Short report
Lack of response to octreotide in Cushing's syndrome due to
metastatic adrenocortical
carcinoma
N N Chan, A J Isaacs
Department of
Endocrinology, Imperial College School of Medicine, Chelsea & Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
Correspondence to: Dr NN Chan, 81 Sherbrooke Road, Fulham, London SW6 7QL, UK
Accepted 22 June 1998
Functional metastatic adrenocortical carcinoma is an uncommon
cause of Cushing's syndrome, which rarely responds to conventional treatment. A patient presenting with Cushing's syndrome secondary to
adrenocortical carcinoma underwent surgical resection.
Post-operatively, she developed metastatic disease resistant to
conventional chemotherapy. Octreotide, a somatostatin analogue which is
effective in the treatment of several types of neuroendocrine tumour,
was tried to ameliorate her secretory symptoms, but without any
therapeutic effect.
Keywords: adrenocortical carcinoma; Cushing's syndrome; octreotide
© 1999 by The Fellowship of Postgraduate Medicine
This article has been cited by other articles:
-
DE HERDER, W W, LAMBERTS, S W J
(1999). Octapeptide somatostatin-analogue therapy of Cushing's syndrome. Postgrad. Med. J.
75: 65-66
[Full Text]
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
